$12.48
0.64% day before yesterday
Nasdaq, Dec 27, 10:08 pm CET
ISIN
US92556V1061
Symbol
VTRS

Viatris Stock price

$12.48
-0.74 5.60% 1M
+2.00 19.08% 6M
+1.65 15.24% YTD
+1.71 15.88% 1Y
-1.19 8.71% 3Y
-7.24 36.71% 5Y
-45.41 78.44% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.08 0.64%
ISIN
US92556V1061
Symbol
VTRS
Sector
Industry

Key metrics

Market capitalization $14.90b
Enterprise Value $28.94b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 14.85
EV/Sales (TTM) EV/Sales 1.93
P/S ratio (TTM) P/S ratio 0.99
P/B ratio (TTM) P/B ratio 0.75
Dividend yield 3.85%
Last dividend (FY24) $0.48
Revenue growth (TTM) Revenue growth -2.55%
Revenue (TTM) Revenue $15.03b
EBIT (operating result TTM) EBIT $1.42b
Free Cash Flow (TTM) Free Cash Flow $1.95b
Cash position $1.98b
EPS (TTM) EPS $-0.74
P/E forward 72.59
P/S forward 1.00
EV/Sales forward 1.95
Short interest 1.96%
Show more

Is Viatris a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Viatris Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Viatris forecast:

1x Buy
10%
7x Hold
70%
2x Sell
20%

Analyst Opinions

10 Analysts have issued a Viatris forecast:

Buy
10%
Hold
70%
Sell
20%

Financial data from Viatris

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
15,025 15,025
3% 3%
100%
- Direct Costs 8,877 8,877
2% 2%
59%
6,149 6,149
4% 4%
41%
- Selling and Administrative Expenses 1,131 1,131
104% 104%
8%
- Research and Development Expense 801 801
2% 2%
5%
4,216 4,216
16% 16%
28%
- Depreciation and Amortization 2,791 2,791
6% 6%
19%
EBIT (Operating Income) EBIT 1,425 1,425
31% 31%
9%
Net Profit -883 -883
148% 148%
-6%

In millions USD.

Don't miss a Thing! We will send you all news about Viatris directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Viatris Stock News

Negative
Reuters
6 days ago
Viatris said on Monday it has received a warning letter from the U.S. Food and Drug Administration after an inspection at its oral finished dose manufacturing facility in Indore, India earlier this year.
Neutral
PRNewsWire
11 days ago
Biomarker data from CARE study characterizing cenerimod's mechanism of action in systemic lupus erythematosus also published in the Annals of the Rheumatic Diseases PITTSBURGH , Dec. 18, 2024 /PRNewswire/ --  Viatris Inc.  (NASDAQ: VTRS) today announced the publication of Phase 2b CARE study results evaluating the efficacy and safety of cenerimod in adults with moderate-to-severe systemic lupus...
Neutral
GlobeNewsWire
27 days ago
Management to Participate in 7th Annual Evercore HealthCONx Conference Management to Participate in 7th Annual Evercore HealthCONx Conference
More Viatris News

Company Profile

Viatris, Inc. engages in the commercialization and manufacturing of pharmaceutical products. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Head office United States
CEO Scott Smith
Employees 38,000
Founded 2019
Website www.viatris.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today